Evaluation of an improved sustained-release buprenorphine formulation for use in mice

American Journal of Veterinary Research

Volumn 75, Issue 7, 2014, Pages 619-625

  Healy, Jason R ^a   Tonkin, Jennifer L ^b,c   Kamarec, Stacey R ^b   Saludes, Mitchell A ^b   Ibrahim, Sherif Y ^b   Matsumoto, Rae R ^a   Wimsatt, Jeffrey H ^b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; BREATHING RATE; CATALEPSY; CONTROLLED STUDY; GASTROINTESTINAL MOTILITY; HOT PLATE TEST; LATENT PERIOD; MALE; MOUSE; NOCICEPTION; NONHUMAN; SUSTAINED RELEASE FORMULATION; TAIL FLICK TEST;

ANALGESICS, OPIOID; ANIMALS; BUPRENORPHINE; DELAYED-ACTION PREPARATIONS; MALE; MICE; PAIN; PAIN MEASUREMENT; RANDOM ALLOCATION;

EID: 84903301690     PISSN: 00029645     EISSN: 19435681     Source Type: Journal    
DOI: 10.2460/ajvr.75.7.619     Document Type: Article

References (45)

1. Roughan JV, Flecknell PA. Buprenorphine: a reappraisal of its antinociceptive effects and therapeutic use in alleviating postoperative pain in animals. Lab Anim 2002;36:322-343.
2. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003;349:949-958.
3. Huang P, Kehner GB, Cowan A, et al. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001;297:688-695.
4. Martin WR, Eades CG, Thompson JA, et al. The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976;197:517-532.
5. Bloms-Funke P, Gillen C, Schuettler AJ, et al. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides 2000;21:1141-1146.
6. Hawkinson JE, Acosta-Burruel M, Espitia SA. Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors. Eur J Pharmacol 2000;389:107-114.
7. Negus SS, Bidlack JM, Mello NK, et al. Delta opioid antagonist effects of buprenorphine in rhesus monkeys. Behav Pharmacol 2002;13:557-570.
8. Leander JD. Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology 1987;26:1445-1447.
9. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978;35:501-516.
10. Cowan A, Doxey JC, Harry EJ. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol 1977;60:547-554.
11. Lizasoain I, Leza JC, Lorenzo P. Buprenorphine: bell-shaped dose-response curve for its antagonist effects. Gen Pharmacol 1991;22:297-300.
12. Christoph T, Kogel B, Schiene K, et al. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 2005;507:87-98.
13. Stokes EL, Flecknell PA, Richardson CA. Reported analgesic and anaesthetic administration to rodents undergoing experimental surgical procedures. Lab Anim 2009;43:149-154.
14. Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage 2005;29:297-326.
15. Bell JR, Butler B, Lawrance A, et al. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009;104:73-77.
16. Evans HC, Easthope SE. Transdermal buprenorphine. Drugs 2003;63:1999-2012.
17. Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2003;25:150-168.
18. Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009;13:219-230.
19. Foley PL, Liang H, Crichlow AR. Evaluation of a sustainedrelease formulation of buprenorphine for analgesia in rats. J Am Assoc Lab Anim Sci 2011;50:198-204.
20. Foley PL, Henderson AL, Bissonette EA, et al. Evaluation of fentanyl transdermal patches in rabbits: blood concentrations and physiologic response. Comp Med 2001;51:239-244.
21. Gades NM, Danneman PJ, Wixson SK, et al. The magnitude and duration of the analgesic effect of morphine, butorphanol, and buprenorphine in rats and mice. Contemp Top Lab Anim Sci 2000;39:8-13.
22. Flecknell PA. Chapter 5. In: Flecknell P, ed. Laboratory animal anaesthesia. 3rd ed. New York: Academic Press, 2009;160.
23. Carbone ET, Lindstrom KE, Diep S, et al. Duration of action of sustained-release buprenorphine in 2 strains of mice. J Am Assoc Lab Anim Sci 2012;51:815-819.
24. Middleton JC, Tipton AJ. Synthetic biodegradable polymers as orthopedic devices. Biomaterials 2000;21:2335-2346.
25. Perrin DEEJ. Polycaprolactone. In: Domb AJKJ, Wiseman DM, eds. Handbook of biodegradable polymers. Amsterdam: Harwood Academic Publishers, 1997;63-78.
26. Perrin DEEJ. Polyglycolide and polylactide. In: Domb AJKJ, Wiseman DM, eds. Handbook of biodegradable polymers. Amsterdam: Harwood Academic Publishers, 1997;3-27.
27. Gunatillake PA, Adhikari R. Biodegradable synthetic polymers for tissue engineering. Eur Cell Mater 2003;5:1-16.
28. Ide S, Minami M, Satoh M, et al. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice. Neuropsychopharmacology 2004;29:1656-1663.
29. Codd EE, Carson JR, Colburn RW, et al. JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence. J Pharmacol Exp Ther 2009;329:241-251.
30. Langford DJ, Bailey AL, Chanda ML, et al. Coding of facial expressions of pain in the laboratory mouse. Nat Methods 2010;7:447-449.
31. Matsumiya LC, Sorge RE, Sotocinal SG, et al. Using the Mouse Grimace Scale to reevaluate the efficacy of postoperative analgesics in laboratory mice. J Am Assoc Lab Anim Sci 2012;51:42-49.
32. Jablonski P, Howden BO, Baxter K. Influence of buprenorphine analgesia on post-operative recovery in two strains of rats. Lab Anim 2001;35:213-222.
33. Brennan MP, Sinusas AJ, Horvath TL, et al. Correlation between body weight changes and postoperative pain in rats treated with meloxicam or buprenorphine. Lab Anim (N Y) 2009;38:87-93.
34. Wala EP, Holtman JR Jr. Buprenorphine-induced hyperalgesia in the rat. Eur J Pharmacol 2011;651:89-95.
35. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician 2008;11:S105-S120.
36. Dahan A, Yassen A, Bijl H, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 2005;94:825-834.
37. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994;55:569-580.
38. Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006;96:627-632.
39. Houmes RJ, Voets MA, Verkaaik A, et al. Efficacy and safety of tramadol versus morphine for moderate and severe postoperative pain with special regard to respiratory depression. Anesth Analg 1992;74:510-514.
40. Wilder-Smith CH, Hill L, Wilkins J, et al. Effects of morphine and tramadol on somatic and visceral sensory function and gastrointestinal motility after abdominal surgery. Anesthesiology 1999;91:639-647.
41. Liles JH, Flecknell PA. The effects of buprenorphine, nalbuphine and butorphanol alone or following halothane anaesthesia on food and water consumption and locomotor movement in rats. Lab Anim 1992;26:180-189.
42. Roughan JV, Flecknell PA. Effects of surgery and analgesic administration on spontaneous behaviour in singly housed rats. Res Vet Sci 2000;69:283-288.
43. Carregaro AB, Luna SP, Mataqueiro MI, et al. Effects of buprenorphine on nociception and spontaneous locomotor activity in horses. Am J Vet Res 2007;68:246-250.
44. Marquez P, Baliram R, Kieffer BL, et al. The mu opioid receptor is involved in buprenorphine-induced locomotor stimulation and conditioned place preference. Neuropharmacology 2007;52:1336-1341.
45. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev 1987;94:469-492.